Xenetic Biosciences, Inc. (XBIO) AI Stock Analysis
XBIO AI stock analysis summary
AI ResearchXenetic Biosciences, Inc. (XBIO) is a biopharmaceutical company focused on developing cell-based oncology therapies and drug delivery technologies. For the trailing twelve months, the company generated $3.3M in revenue alongside an operating margin of -147.1% and a net profit margin of -75.9%. As of June 30, 2026, Xenetic maintained $6.5M in cash and short-term investments against a market capitalization of $4.7M.
- Market cap
- $4.7M
- Revenue (TTM)
- $3.3M
- P/E
- —
- 1Y return
- -54.7% S&P 500 16.8%
- Avg. target
- $40.00 1910.1% vs last close
Bull case
- Xenetic produced a 5-year revenue CAGR of 46.8% from FY2020 through FY2025, reaching $3.0M in FY2025.
- The balance sheet remains liquid with $6.5M in cash and short-term investments and a current ratio of 7.43 as of June 30, 2026.
- The company demonstrated consistent execution against expectations by beating consensus EPS estimates in 4 of its last 4 quarters.
Bear case
- The company continues to operate at a loss, reporting FY2025 net income of -$2.7M and a trailing twelve-month profit margin of -75.9%.
- Shareholder equity has been diluted over time, with the 5-year share count expanding by 124.5%.
- Stock performance has lagged significantly, dropping 54.7% over the past year and 88.9% over five years.
What Xenetic Biosciences does
Xenetic Biosciences, Inc. is a biopharmaceutical company advancing innovative therapies in oncology. The company is developing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens, specifically addressing B-cell lymphomas by targeting the B-cell receptor on malignant tumor cells. In addition to its oncology research, Xenetic utilizes PolyXen, a proprietary drug delivery platform that facilitates partnerships with pharmaceutical and biotechnology companies. Xenetic has established collaborations with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. The company is headquartered in Framingham, Massachusetts.
Growth and profitability
From FY2020 to FY2025, Xenetic generated a 5-year revenue CAGR of 46.8%. Annual revenue grew from $1.2M in FY2021 to $1.7M in FY2022, reached $2.5M in FY2023, remained at $2.5M in FY2024, and expanded 19.0% to $3.0M in FY2025. Gross margin was 100.0% in all five fiscal years. Operating margins remained negative, moving from -495.1% in FY2021 to -95.2% in FY2025. Net losses decreased over the period from -$5.6M in FY2021 to -$2.7M in FY2025. For the latest quarter ended June 30, 2026, quarterly revenue increased 12.0% year-over-year, while trailing twelve-month revenue reached $3.3M with an EPS of -$1.15.
Balance sheet and cash flow
As of June 30, 2026, Xenetic held $6.5M in cash and short-term investments, with total assets of $7.0M and shareholders' equity of $6.1M. The company reported a current ratio of 7.43. Cash flow remains negative, as FY2025 operating cash flow and free cash flow both stood at -$2.3M, improved from -$4.7M in FY2021. Xenetic does not pay dividends or repurchase shares, while its 5-year share count increased 124.5%.
Valuation and performance
Xenetic trades at a price-to-sales ratio of 1.4x, which is below the 4.1x median of its US-listed Healthcare peers. Its enterprise value to revenue stands at 0.1x, and EV-to-EBITDA is 1.0x compared to the peer median of 12.0x. Xenetic carries an enterprise value of -$613,814 and a market capitalization of $4.7M. Over the past year, the stock fell 54.7%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock fell 88.9% compared to an 83.0% gain for SPY.
What analysts expect
One analyst covers Xenetic for the next fiscal year, with a mean price target of $40.00 compared to the last close of $1.99, representing a 1910.1% upside target. Xenetic exceeded EPS estimates in all 4 of the last 4 quarters. For the fiscal year ending December 31, 2026, consensus estimates expect revenue of $0 and EPS of -$3.32. For the following fiscal year, analysts estimate revenue of $1.9M and EPS of -$0.34. The next earnings date is November 11, 2026.
Key risks and what to watch
- Operating cash burn remains a factor, with FY2025 free cash flow at -$2.3M relative to $6.5M in cash and short-term investments.
- Consensus estimates project revenue to fall to $0 for the fiscal year ending December 31, 2026.
- High volatility is indicated by a beta of 2.20 and a share price trading 30.3% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XBIO AI stock analysis
This page is an AI-written research summary of Xenetic Biosciences, Inc. (XBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XBIO income statement, XBIO balance sheet, XBIO key metrics, XBIO analyst forecast, XBIO chart. See the XBIO stock overview for the latest quote and news.
XBIO AI stock analysis FAQ
Does Xenetic Biosciences pay a dividend?
No, Xenetic Biosciences does not pay a dividend. The company uses its cash resources to fund research and operations, reporting free cash flow of -$2.3M in FY2025.
What is Xenetic Biosciences' current cash balance?
As of June 30, 2026, Xenetic reported $6.5M in cash and short-term investments, with a current ratio of 7.43.
What is the analyst price target for XBIO stock?
The mean analyst price target is $40.00, which is 1910.1% above its October 16, 2026 closing price of $1.99.
When is Xenetic Biosciences reporting earnings next?
Xenetic Biosciences is scheduled to report its next earnings on November 11, 2026.